These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
24. [Discovery of a New Siderophore Cephalosporin, Cefiderocol]. Yamano Y Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471 [TBL] [Abstract][Full Text] [Related]
25. An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms. Domingues S; Lima T; Saavedra MJ; Da Silva GJ Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511802 [TBL] [Abstract][Full Text] [Related]
26. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. Kaye KS; Marchaim D; Thamlikitkul V; Carmeli Y; Chiu CH; Daikos G; Dhar S; Durante-Mangoni E; Gikas A; Kotanidou A; Paul M; Roilides E; Rybak M; Samarkos M; Sims M; Tancheva D; Tsiodras S; Kett D; Patel G; Calfee D; Leibovici L; Power L; Munoz-Price S; Stevenson K; Susick L; Latack K; Daniel J; Chiou C; Divine GW; Ghazyaran V; Pogue JM NEJM Evid; 2023 Jan; 2(1):. PubMed ID: 37538951 [TBL] [Abstract][Full Text] [Related]
27. Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1. Lasarte-Monterrubio C; Guijarro-Sánchez P; Vázquez-Ucha JC; Alonso-Garcia I; Alvarez-Fraga L; Outeda M; Martinez-Guitian M; Peña-Escolano A; Maceiras R; Lence E; González-Bello C; Arca-Suárez J; Bou G; Beceiro A Antimicrob Agents Chemother; 2023 May; 67(5):e0150522. PubMed ID: 37195077 [TBL] [Abstract][Full Text] [Related]
28. Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei. Hall CM; Somprasong N; Hagen JP; Nottingham R; Sahl JW; Webb JR; Mayo M; Currie BJ; Podin Y; Wagner DM; Keim P; Schweizer HP Antimicrob Agents Chemother; 2023 Jun; 67(6):e0017123. PubMed ID: 37133377 [TBL] [Abstract][Full Text] [Related]
29. Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Mazzitelli M; Gregori D; Sasset L; Trevenzoli M; Scaglione V; Lo Menzo S; Marinello S; Mengato D; Venturini F; Tiberio I; Navalesi P; Cattelan A Microorganisms; 2023 Apr; 11(4):. PubMed ID: 37110408 [TBL] [Abstract][Full Text] [Related]
30. In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains. Padovani M; Bertelli A; Corbellini S; Piccinelli G; Gurrieri F; De Francesco MA Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107147 [TBL] [Abstract][Full Text] [Related]
31. Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in Sadek M; Bosch Duran J; Poirel L; Nordmann P Antimicrob Agents Chemother; 2023 May; 67(5):e0007823. PubMed ID: 37039645 [TBL] [Abstract][Full Text] [Related]
32. Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure Kocer K; Boudour-Halil D; Chanthalangsy Q; Sähr A; Heeg K; Boutin S; Nurjadi D Antimicrob Agents Chemother; 2023 May; 67(5):e0011823. PubMed ID: 37022155 [TBL] [Abstract][Full Text] [Related]
33. Resistance to Some New Drugs and Prevalence of ESBL- and MBL-Producing Enterobacteriaceae Uropathogens Isolated from Diabetic Patients. Alzahrani OM; Uddin F; Mahmoud SF; Alswat AS; Sohail M; Youssef M Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556490 [TBL] [Abstract][Full Text] [Related]
35. Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant He Y; Wang Y; Ma X; Zhao L; Guan J; Zhao J; Yu W; Li Y; Ni W; Gao Z Infect Drug Resist; 2022; 15():7177-7187. PubMed ID: 36514799 [TBL] [Abstract][Full Text] [Related]
36. Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa. Sadek M; Le Guern R; Kipnis E; Gosset P; Poirel L; Dessein R; Nordmann P Eur J Clin Microbiol Infect Dis; 2023 Jan; 42(1):61-66. PubMed ID: 36376766 [TBL] [Abstract][Full Text] [Related]
37. Nosocomial outbreak by NDM-1-producing Coppi M; Antonelli A; Niccolai C; Bartolini A; Bartolini L; Grazzini M; Mantengoli E; Farese A; Pieralli F; Mechi MT; Di Pilato V; Giani T; Rossolini GM Euro Surveill; 2022 Oct; 27(43):. PubMed ID: 36305334 [TBL] [Abstract][Full Text] [Related]
38. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium. Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010 [TBL] [Abstract][Full Text] [Related]
39. Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit. Smoke SM; Brophy A; Reveron S; Iovleva A; Kline EG; Marano M; Miller LP; Shields RK Clin Infect Dis; 2023 Feb; 76(3):e1261-e1265. PubMed ID: 35974429 [TBL] [Abstract][Full Text] [Related]
40. Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence. Sansone P; Giaccari LG; Coppolino F; Aurilio C; Barbarisi A; Passavanti MB; Pota V; Pace MC Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]